FDA approved Awiqli (insulin icodec-abae) 700 units/mL on March 27, 2026 — ~2 months ahead of the projected May 29 PDUFA. First and only once-weekly basal insulin for adults with type 2 diabetes, reducing basal injections from seven to one per week. Based on ONWARDS Phase 3a programme. Nationwide US launch expected 2H 2026.
About
Type 2 diabetes is a chronic condition where the body struggles to regulate blood sugar, leading to fatigue, frequent urination, and serious long-term complications like heart disease and nerve damage. Awiqli is a once-weekly insulin injection that provides steady blood sugar control by mimicking the body’s natural insulin over seven days. This could simplify treatment for patients who currently need daily injections while maintaining similar blood sugar management.
